Jul 24, 2018 7:30am EDT GSK and Adaptimmune Complete Transition of NY-ESO SPEAR T-cell Therapy Program to GSK
Jul 18, 2018 7:29am EDT Adaptimmune Announces Favorable Review of Safety from One Billion Cell Dose Cohort in MAGE-A10 SPEAR T-cell Study and Initiation of Third Dosing Cohorts
Jun 11, 2018 7:30am EDT Study published in Cancer Discovery Indicates that NY-ESO SPEAR T-cells are Long-lived, Self‑renewing, and Capable of Persistent Anti-Tumor Effects
Jun 04, 2018 7:30am EDT Adaptimmune Presents Detailed Safety Update from Ongoing MAGE-A10 Pilot Studies at ASCO
Jun 04, 2018 7:30am EDT Adaptimmune Announces First Patient to Receive One Billion Target Cell Dose after Positive Safety Data from Pilot Study with MAGE-A4 SPEAR T-cells
Jun 02, 2018 8:00am EDT Updated Myxoid/Round Cell Liposarcoma Data with NY-ESO, Presented at ASCO Annual Meeting, Further Supports Promising Benefit: Risk Profile
May 16, 2018 5:00pm EDT Myxoid/Round Cell Liposarcoma Data with NY-ESO and MAGE-A10 Study Update to be Presented at American Association for Clinical Oncology (ASCO) Annual Meeting
Apr 25, 2018 8:00am EDT Adaptimmune to Report First Quarter 2018 Financial Results and Business Update on Wednesday May 9, 2018
Apr 16, 2018 2:00pm EDT Adaptimmune Presents MAGE-A4 and MAGE-A10 pre-clinical data at American Association for Cancer Research (AACR) Annual Meeting
